Daiichi Sankyo Europe Gmbh
Daiichi Sankyo Europe Gmbh (Germany) holds 0 active US FDA Type II Drug Master Files and 2 inactive and is linked to 1 FDA-registered manufacturing site. 3 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Daiichi Sankyo Europe Gmbh: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/daiichi-sankyo-europe-gmbh
Overview
Daiichi Sankyo Europe Gmbh is a pharmaceutical company headquartered in München, Germany.
API / Drug Master Files
Daiichi Sankyo Europe Gmbh holds 0 active (2 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- CS-866-HYDROCHLOROTHIAZIDE TABLETS (CS-866HCTZ)Inactive2002-05-31
- CS-866(5 10 20 & 40MG) TABLETSInactive2000-05-15
Registered manufacturing sites (1)
Physical sites registered with the US FDA and resolved to Daiichi Sankyo Europe Gmbh, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
FDA compliance signals
3 FDA enforcement records linked to this company.
- 4832025-07-18
Written procedures not established/followed
- 4832025-07-18
Investigations of discrepancies, failures
- 4832025-07-18
Complete test data included in records
Is this Daiichi Sankyo Europe Gmbh?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.